Clinical trials: 1st-line Treatment
Esophageal Cancer by AJCC V8 Stage
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line
- Trial name
- NCT05738434
- Testing
- Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab
- Where
- China
- Volunteers
- 188 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
SCLC,Extensive Stage
TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors
To Evaluate the Safety and Efficacy of Thoracic Radiotherapy for?ES-SCLC After First Line Treatment with Immune Checkpoint Inhibitors.
- Trial name
- NCT05544149
- Testing
- Thoracic radiotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer. The study will compare lenvatinib plus tislelizumab with or without gefitinib.
- Trial name
- LENTIG-HCC (NCT07829926)
- Testing
- Lenvatinib, Tislelizumab, Gefitinib
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Extensive-stage Small-cell Lung Cancer
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
This is an open-label, single arm Phase II study designed to observe and evaluate the efficacy and safety of sequential thoracic radiotherapy in the first-line treatment of extensive small cell lung cancer with chemotherapy…
- Trial name
- NCT06586697
- Testing
- Thoracic Radiotherapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer Stage IV, Oligometastatic Disease
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy…
- Trial name
- TAORMINA (NCT05377047)
- Testing
- SABR
- Where
- 19 sites in Ireland, Israel and 4 more
- Volunteers
- 345 people
- Sponsor
- Vastra Gotaland Region
CD30-Positive Peripheral T-Cell Lymphoma
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
The goal of this observational study is to evaluate how well brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (CHP) works and how safe it is when used as first-line treatment in adults with CD30-positive…
- Trial name
- NCT07624838
- Testing
- Brentuximab Vedotin Plus CHP
- Where
- 37 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Gastric Cancer
Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Study H3E-MW- S108 is a multicenter, single arm, open-label Phase 2 study to determine the response rate of pemetrexed plus cisplatin in patients with Stage IV gastric cancer, not amenable to curative surgery, or recurrence after…
- Trial name
- NCT00415168
- Testing
- pemetrexed, cisplatin
- Where
- 6 sites in Russia
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
HRAS Gene Mutation, HNSCC
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN).
- Trial name
- AIM-HN/SEQ-HN (NCT03719690)
- Testing
- Tipifarnib, HRAS Detection Assay
- Where
- 102 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Kura Oncology, Inc.
Gastroesophageal Junction Adenocarcinoma
To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
To evaluate the efficacy of CT041 in sequential treatment after first-line treatment of advanced gastric/esophagogastric junction adenocarcinoma
- Trial name
- NCT07179484
- Testing
- CT041 autologous CAR T-cell injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing GoBroad Hospital
Metastatic Castration-Resistant Prostate Cancer
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
The purpose of this study is to evaluate the percentage of participants achieving prostate-specific antigen (PSA) response by 12 weeks of therapy from baseline according to Prostate Cancer Clinical Trials Working Group (PCWG2)…
- Trial name
- NCT02405858
- Testing
- Abiraterone Acetate, Prednisolone
- Where
- 14 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Janssen Pharmaceutical K.K.
Small Cell Lung Carcinoma
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
This is the first study where BAY1000394 is given in combination with chemotherapy: cisplatin / etoposide or carboplatin / etoposide. Patients with small cell lung cancer will be treated.
- Trial name
- NCT01573338
- Testing
- Roniciclib (BAY1000394), Etoposide, Cisplatin
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 43 people
- Sponsor
- Bayer
Cervical Cancer
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
- Trial name
- NCT06755515
- Testing
- Rulonilimab, cisplatin/carboplatin + paclitaxel ± bevacizumab
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Non-Small Cell Lung Cancer
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
A single arm, open label, phase IV trial to evaluate safety and efficacy of icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR.
- Trial name
- NCT01646450
- Testing
- Icotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Gastric Cancer
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced…
- Trial name
- NCT00952497
- Testing
- Cisplatin, Capecitabine, Telatinib
- Where
- 11 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- ACT Biotech, Inc
Colorectal Cancer Stage IV
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective in first line as the same regimen given continuously, resulting in a Time to Treatment Failure (TTF) not inferior to that obtained…
- Trial name
- IMPROVE-2 (NCT06509126)
- Testing
- Panitumumab, Irinotecan, 5-fluorouracil
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute, Naples
Advanced Colorectal Cancer
Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU
Phase II study of simultaneous infusion of levozolinate for injection and 5-FU as first-line treatment for advanced colorectal cancer
- Trial name
- NCT07391618
- Testing
- mFOLFOX/FOLFIRI ( Standard Chemotherapy)
- Where
- China
- Volunteers
- 583 people
- Sponsor
- Chinese PLA General Hospital
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05172258
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 20 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT…
- Trial name
- GLORIA (NCT04121455)
- Testing
- Olaptesed pegol, Radiotherapy, Bevacizumab
- Where
- 6 sites in Germany
- Volunteers
- 117 people
- Sponsor
- TME Pharma AG
Small Cell Lung Cancer Extensive Stage
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the…
- Trial name
- NCT04967625
- Testing
- Sintilimab, Anlotinib hydrochloride
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
Non Small Cell Lung Cancer
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally…
- Trial name
- NCT00441740
- Testing
- Vinorelbine, Gemcitabine, Docetaxel
- Where
- 9 sites in Greece
- Volunteers
- 419 people
- Sponsor
- Hellenic Oncology Research Group